MAIA — Maia Biotechnology Share News
0.000.00%
Last trade - 00:00Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale
Brief: Maia Biotechnology Announces Open Market Purchases By CEO And Directors
Brief: Maia Biotechnology Announces $736,600 Private Placement
Brief: Maia Biotechnology announces $2.25 million private placement
Brief: MAIA Biotechnology Highlights Positive Efficacy Data From THIO-101 Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Receives FDA’S Fast Track Designation For Ateganosine As A Treatment For Non-Small Cell Lung Cancer
Brief: MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board
Brief: MAIA Biotechnology Says New Responder In Non-Small Cell Lung Cancer Phase 2 Clinical Trial
Brief: Maia Biotechnology Announces $1.08 Million Private Placement
Brief: MAIA Biotechnology- Phase 2 Trial Thio-101 Expansion Underway Potential Filing In 2026 For Accelerated Approval
Brief: Maia Biotechnology Inc - Decreases Maximum Aggregate Offering Price To $11.2 Million - SEC Filing
Brief: Maia Biotechnology Receives Usan Council Approval For “Ateganosine” As Nonproprietary Name For Anticancer Agent Thio
Brief: Maia Biotechnology Says Lans To Initiate A Phase 3 Pivotal Trial In 2025, Named Thio-104
MAIA Biotechnology rises on lung cancer drug trial data
Brief: MAIA Biotechnology Increased Maximum Offering Price Of Shares Of Common Stock Issuable Under At Market Offering Agreement To $30 Million
Brief: MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer